Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Preterm infants born before the 30th week of pregnancy are especially at risk of perinatal
brain damage which is usually a result of cerebral ischemia or an ascending intrauterine …

The neuro-protective effect of antenatal magnesium sulfate on very preterm infants has been
demonstrated in good-quality randomised controlled trials and meta-analyses. Magnesium …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

The aim of our study was to assess the feasibility of implementing a protocol for the use of
magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included …

Purpose To review the effect of intravenous magnesium in obstetrics on fetal/neonatal
neuroprotection. Methods A systematic review of published studies. Results Five …

Background Strong evidence supports administration of magnesium sulphate prior to birth at
less than 30 weeks' gestation to prevent very preterm babies dying or developing cerebral …

OBJECTIVE: Clinical trials support the efficacy and safety of magnesium sulfate for cerebral
palsy prevention. We evaluated the implementation of a clinical protocol for the use of …

Abstract Background Magnesium sulphate (MgSO 4) is the only treatment approved for fetal
neuroprotection. No information on its use is available in the absence of a national registry …